Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
POLAR BEAR
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
- NCT04332822 ↗
- Recruiting
- Nordic Lymphoma Group
- Deep
We haven't built an HCP commentary report on POLAR BEAR (R-pola-mini-CHP in diffuse large B-cell lymphoma, ≥80 or frail ≥75) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on POLAR BEAR so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 11 | |
| X threads | 7 | |
| Podcasts | 5 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- DLBCL; Diffuse Large B Cell Lymphoma
- Interventions
- R-pola-mini-CHP; R-mini-CHOP
- Arms
- Arm A - R-mini-CHOP · Active comparator
- Arm B - R-pola-mini-CHP · Experimental
- Enrollment
- 300 (estimated)
- Primary outcomes
- Progression-free survival (PFS).
- Sponsor
- Nordic Lymphoma Group with Roche Pharma AG
- Start
- Aug 19, 2020
- Primary completion
- Dec 28, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT04332822 · updated Sep 19, 2024